Stroke, AcutePRALINENCT04118998
Progressive Abduction Loading Therapy
A study testing Abduction Loading and Supported Reaching in people with Stroke, Acute, run by Northwestern University at 3 sites in United States.
Trial summary
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Stroke, Acute
- What is being tested?
- Abduction Loading and Supported Reaching
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 86 participants
- Where
- 3 sitesUnited States
- Study dates
- 27 Aug 2021to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hemiparesis confined to one side, (CMSA Stage 2 or 3 out of 7)
- Stroke impacting parenchyma of the middle cerebral artery distribution
- Within 90 days post-stroke
- 18 to 85 years old
- No or Mild-to-moderate Aphasia (NIHSS #9 Best Language. = 0 or 1- Describe picture; No or Mild-to-moderate Aphasia)
- No or Mild extinction and inattention (NIHSS 11 Extinction and Inattention. = 0 or 1- No abnormality or Inattention to one modality.)
- Ability to perform a 3-step motor command with the unaffected arm
- Capacity to provide informed consent
Who cannot join
- Premorbid and persistent disability or motor impairment of the upper extremities
- Brainstem and/or cerebellar lesion
- Comorbidity medically contraindicating motor assessments
- Any other chronic neurological condition
- Pain or hypersensitivity limiting motor assessments
- Limb edema limiting study motor assessments
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Department of Physical Therapy and Human Movement Sciences
Chicago, Illinois, 60611
Shirley Ryan AbilityLab
Chicago, Illinois, 60611
Northwestern Medicine Marianjoy Rehabilitation Hospital
Wheaton, Illinois, 60187
About this study
Official title: Progressive Abduction Loading Therapy: A Phase IIb Stroke Rehabilitation Trial With Longitudinal Tracking
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Participants with acute/subacute stroke will receive one of two study interventions in addition to prescribed therapies in both inpatient rehabilitation and day-rehab. Participants will be followed for 1 year.
Read the detailed description
Eighty-six individuals with acute (admission to in-patient rehabilitation) severe hemiparetic stroke (Chedoke McMaster Stroke Assessment arm score of Stage 2 or 3 out of 7) will participate in this study. All participants will be recruited upon admission to the Shirley Ryan AbilityLab (formally Rehabilitation Institute of Chicago) for stroke rehabilitation under the administration of the study physician. Participants will receive experimental or comparison group therapy as adjuvant to regular in-patient and day-rehabilitation therapy. Participants will be evaluated weekly while in therapy and then bimonthly (every other month) after discharge until 1-year following baseline evaluation.
From the admission evaluations by the study physician and other rehabilitation services, patients with adequate language, visuospatial, cognitive and motor function will be consented for participation and then screened by a study evaluation physical therapist and board-certified neurological clinical specialist for the specific motor inclusion criteria. After consent, a REDCap screening form will be initiated by the study physician's project coordinator with relevant data from the participant medical record. The study evaluation therapist will then conduct the screening that will include verification and completion of the inclusion/exclusion criteria and the transcranial magnetic stimulation (TMS) safety checklist that will identify any contraindication to TMS-based assessment of motor evoked potentials (MEPs). The Chedoke McMaster Stroke Assessment (primary motor inclusion criteria) is very time efficient reducing interference with in-patient therapy activities and rapidly identifying individuals with severe impairment facilitating participant recruitment. The study evaluation therapist will not need to complete the entire assessment instead only confirming patients at level 2 and 3 out of 7 for inclusion. The REDCap screening form and TMS checklist will be reviewed by the study physician. The study physician will grant medical clearance for TMS-based MEP assessment and participation in the study.
Regarding motor criteria; participants not meeting the minimum of Stage 2 out of 7 on the Chedoke McMaster Stroke Assessment will be monitored for emergence of adequate movement. Shirley Ryan AbilityLab therapists routinely report Chedoke scores in daily documentation. The study physician and project coordinator will notify the study evaluation therapist once minimal movement emerges in these patients and the screening process can be initiated. Participants who subsequently pass screening and medical clearance for TMS-based MEP assessment will undergo conventional MEP assessment. Participants will later be randomly allocated to either the experimental or comparison treatment groups within REDCap by the study intervention therapist upon the first intervention session. The REDCap randomization algorithm is managed by the study biostatistics team and employs a concealed allocation table. The allocation table is constructed to balance the allocation of participants (2 groups of n=43) by sex, presence or absence of MEPs, and level of severity as measured by the Fugl-Meyer Arm Motor Assessment in order to ensure equivalent baseline characteristics of each group. The Fugl-Meyer score will be divided in bins of 6 points. Participants, evaluation therapists, biostatisticians, and the study PD/PI will be blinded to group assignment. Intervention therapists and the study physician will not be blinded to group assignment. Participants will not be able to tell the difference between interventions since both will involve reaching practice. Participants that are not medically cleared for TMS-based MEP assessment will be randomly allocated to group without MEP status. It is anticipated that only 1-2% of participants will not be cleared for MEP assessment.
Baseline and subsequent evaluations will include a kinematic/kinetic measurement of reaching function (primary endpoint, reaching distance under standardized abduction loading, normal gravity) and a kinematic/kinetic measurement of shoulder/elbow impairment (secondary endpoint, loss of independent joint control). The primary and secondary endpoints will be conducted at Shirley Ryan AbilityLab during both in-patient and day-rehabilitation by the study evaluation therapist under following initial training and certification by the study PD/PI. Standardized clinical evaluations of arm impairment, activity limitation, and participation restriction will also be performed during this phase at Shirley Ryan AbilityLab by the study evaluation therapist who will be blinded to intervention group. Evaluations will take place at baseline, weekly until discharge from rehabilitation, and then bimonthly until 12 months post-baseline measurement. Following discharge from rehabilitation, patients will receive follow-up evaluations bimonthly at Northwestern University Department of Physical Therapy and Human Movement Sciences. These evaluations will be conducted by a second study evaluation therapist and board-certified neurological clinical specialist following initial training and certification by the study PD/PI. The second study evaluation therapist will also serve as the backup for the first study evaluation therapist in case of illness/absence.
During in-patient rehabilitation and day-rehabilitation, experimental and comparison intervention sessions will parallel regular therapy and be conducted at Shirley Ryan AbilityLab and Streeterville Day Rehabilitation Center respectively by two Shirley Ryan AbilityLab study intervention therapists. Study intervention therapists will be initially trained and certified by the study PD/PI. Study intervention sessions will be 5 days per week during in-patient therapy and 3 days per week during day-rehabilitation. The intervention period for both groups will be ~45 minutes (truncated at 1 hour) in addition to the regular therapy schedule until discharge. Both interventions will involve performing standardized reaching exercises to outward targets displayed on a monitor. The experimental group receiving progressive abduction loading therapy will practice reaching exercises with abduction loading and the comparison group will practice reaching supported on a horizontal haptic table. All participants will have the same maximum number of sets and repetitions of exercise during sessions and the sessions will be truncated at 60 minutes of total contact time. Half of the enrolled participants are expected to transition to day-rehabilitation following in-patient rehabilitation. In day-rehabilitation, participants will continue to receive the same study intervention but only 3 days per week matching the day-rehabilitation schedule.
- Conditions
- Stroke, Acute
- Being tested
- Abduction Loading, Supported Reaching
- Keywords
- Rehabilitation, Arm, Flexion Synergy, Longitudinal, Targetted, Quantitative
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Abduction LoadingBehavioural
Also called Progressive Abduction Loading Therapy
The intervention for the experimental group entails practicing reaching with abduction loading.
Supported ReachingBehavioural
The intervention for the active comparator entails practicing reaching while supported.
| Study group | Role | What they receive |
|---|---|---|
| Abduction Loading | Experimental | The intervention for the experimental group entails practicing reaching with abduction loading. Receives: Behavioral: Abduction Loading |
| Supported Reaching | Active comparator | The intervention for the active comparator entails practicing reaching while supported. Receives: Behavioral: Supported Reaching |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Reaching Function
Quantitative evaluation of reaching by calculating distance from reaching kinematics data during ballistic outward reaches against gravity.
Measured: Change in Reaching function will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Secondary outcomes (4)
Change in Loss of Independent Joint Control
Quantitative evaluation of the expression of flexion synergy impairment. Measured as the maximum abduction load achieved during a reach to two standardized targets (near and far).
Measured: Change in Loss of Independent Joint Control will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Fugl-Meyer Motor Assessment
Qualitative and clinical assessment of general motor impairment of arm following stroke. The scale evaluates movement impairment of the arm through observation. The scale ranges from 0-66 points with 66 indicating the best score.
Measured: Change in Fugl-Meyer Motor Assessment will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Action Research Arm Test
Qualitative and clinical assessment of activity limitation (function) of the arm following stroke. The scale focusses on reaching, grasping, and releasing objects of various sizes. The scale ranges from 0-57 with 57 indicating the best score.
Measured: Change in Action Research Arm Test will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Stroke Impact Scale
Structured interview to assess domains of the ICF (International Classification of Functioning, Disability and Health) in individuals following stroke. The domains include self-reported physical problems, memory and thinking, control of emotions, communication, daily activities, home and community mobility, the affected hand, participation and life roles, and global recovery. Each domain score is transformed to a scale of 0-100 with 100 being the best score.
Measured: Change in Stroke Impact Scale will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2019
- Study start27 Aug 2021
- Primary completion7 Jul 2026
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Stroke, AcuteStudies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Shirley Ryan AbilityLab, Marianjoy Rehabilitation Hospital & Clinics
- Responsible party
- Principal investigator, Michael Ellis, Northwestern University
- Investigators
- Michael D Ellis, PT, DPT, Principal investigator, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04118998
- Sponsor's protocol ID
- STU00209671
- Other IDs
- R01HD096071
- Acronym
- PRALINE
- Status last verified
- Aug 2026
- First submitted
- 23 Sep 2019
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Final research data will be shared openly and timely in accordance with NIH Data Sharing Policy (https://grants.nih.gov/grants/policy/data\_sharing/) and NICHD Data and Specimen Hub - Data Archive Policy Statement (https://dash.nichd.nih.gov/Resource/Policies). Data sharing will occur through the primary repositories of NICHD DASH (https://dash.nichd.nih.gov/), Northwestern University DigitalHub (https://digitalhub.northwestern.edu/), and Open Science Framework (https://osf.io/). Data will be exported from the internal RedCap study data base in spreadsheet format and will be deidentified and coded. Data will be available through speaking engagements and publications, presentations at scientific symposia and seminars. Data sharing in the above repositories will be phased in time with acceptance for publication of the primary outcome paper near the end of the fifth year and then with each subsequent publication. Publications will include DOIs for the data repositories.
Publications
Ellis MD, Carmona C, Drogos J, Dewald JPA. Progressive Abduction Loading Therapy with Horizontal-Plane Viscous Resistance Targeting Weakness and Flexion Synergy to Treat Upper Limb Function in Chronic Hemiparetic Stroke: A Randomized Clinical Trial. Front Neurol. 2018 Feb 19;9:71. doi: 10.3389/fneur.2018.00071. eCollection 2018.
PubMed 29515514Ellis MD, Lan Y, Yao J, Dewald JP. Robotic quantification of upper extremity loss of independent joint control or flexion synergy in individuals with hemiparetic stroke: a review of paradigms addressing the effects of shoulder abduction loading. J Neuroeng Rehabil. 2016 Oct 29;13(1):95. doi: 10.1186/s12984-016-0203-0.
PubMed 27794362Ellis MD, Sukal-Moulton T, Dewald JP. Progressive shoulder abduction loading is a crucial element of arm rehabilitation in chronic stroke. Neurorehabil Neural Repair. 2009 Oct;23(8):862-9. doi: 10.1177/1545968309332927. Epub 2009 May 19.
PubMed 19454622Roth HR, Carmona C, Clark G, Gyarmaty JE, Dewald JPA, Giblin E, Harvey RL, Jaskiewicz J, Kim KA, Lancki N, Luhrsen A, Mandana A, Manikonda D, Morris A, Sheth S, Stoykov ME, Young AC, Zielke D, Ellis MD. PRALINE: study protocol for a phase IIb inpatient stroke rehabilitation randomized controlled trial investigating longitudinal outcomes after progressive abduction loading therapy. Trials. 2025 Jul 20;26(1):250. doi: 10.1186/s13063-025-08969-6.
PubMed 40685355
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Progressive Abduction Loading Therapy: A Phase IIb Stroke Rehabilitation Trial With Longitudinal Tracking
- ClinicalTrials.gov ID
- NCT04118998
- Acronym / sponsor ID
- PRALINE / STU00209671
- Conditions
- Stroke, Acute
- Keywords
- Rehabilitation, Arm, Flexion Synergy, Longitudinal, Targetted, Quantitative
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Shirley Ryan AbilityLab, Marianjoy Rehabilitation Hospital & Clinics
- Study start
- 27 Aug 2021 (actual)
- Primary completion
- 7 Jul 2026 (actual)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 8 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Participants with acute/subacute stroke will receive one of two study interventions in addition to prescribed therapies in both inpatient rehabilitation and day-rehab. Participants will be followed for 1 year.
Detailed description
Eighty-six individuals with acute (admission to in-patient rehabilitation) severe hemiparetic stroke (Chedoke McMaster Stroke Assessment arm score of Stage 2 or 3 out of 7) will participate in this study. All participants will be recruited upon admission to the Shirley Ryan AbilityLab (formally Rehabilitation Institute of Chicago) for stroke rehabilitation under the administration of the study physician. Participants will receive experimental or comparison group therapy as adjuvant to regular in-patient and day-rehabilitation therapy. Participants will be evaluated weekly while in therapy and then bimonthly (every other month) after discharge until 1-year following baseline evaluation.
From the admission evaluations by the study physician and other rehabilitation services, patients with adequate language, visuospatial, cognitive and motor function will be consented for participation and then screened by a study evaluation physical therapist and board-certified neurological clinical specialist for the specific motor inclusion criteria. After consent, a REDCap screening form will be initiated by the study physician's project coordinator with relevant data from the participant medical record. The study evaluation therapist will then conduct the screening that will include verification and completion of the inclusion/exclusion criteria and the transcranial magnetic stimulation (TMS) safety checklist that will identify any contraindication to TMS-based assessment of motor evoked potentials (MEPs). The Chedoke McMaster Stroke Assessment (primary motor inclusion criteria) is very time efficient reducing interference with in-patient therapy activities and rapidly identifying individuals with severe impairment facilitating participant recruitment. The study evaluation therapist will not need to complete the entire assessment instead only confirming patients at level 2 and 3 out of 7 for inclusion. The REDCap screening form and TMS checklist will be reviewed by the study physician. The study physician will grant medical clearance for TMS-based MEP assessment and participation in the study.
Regarding motor criteria; participants not meeting the minimum of Stage 2 out of 7 on the Chedoke McMaster Stroke Assessment will be monitored for emergence of adequate movement. Shirley Ryan AbilityLab therapists routinely report Chedoke scores in daily documentation. The study physician and project coordinator will notify the study evaluation therapist once minimal movement emerges in these patients and the screening process can be initiated. Participants who subsequently pass screening and medical clearance for TMS-based MEP assessment will undergo conventional MEP assessment. Participants will later be randomly allocated to either the experimental or comparison treatment groups within REDCap by the study intervention therapist upon the first intervention session. The REDCap randomization algorithm is managed by the study biostatistics team and employs a concealed allocation table. The allocation table is constructed to balance the allocation of participants (2 groups of n=43) by sex, presence or absence of MEPs, and level of severity as measured by the Fugl-Meyer Arm Motor Assessment in order to ensure equivalent baseline characteristics of each group. The Fugl-Meyer score will be divided in bins of 6 points. Participants, evaluation therapists, biostatisticians, and the study PD/PI will be blinded to group assignment. Intervention therapists and the study physician will not be blinded to group assignment. Participants will not be able to tell the difference between interventions since both will involve reaching practice. Participants that are not medically cleared for TMS-based MEP assessment will be randomly allocated to group without MEP status. It is anticipated that only 1-2% of participants will not be cleared for MEP assessment.
Baseline and subsequent evaluations will include a kinematic/kinetic measurement of reaching function (primary endpoint, reaching distance under standardized abduction loading, normal gravity) and a kinematic/kinetic measurement of shoulder/elbow impairment (secondary endpoint, loss of independent joint control). The primary and secondary endpoints will be conducted at Shirley Ryan AbilityLab during both in-patient and day-rehabilitation by the study evaluation therapist under following initial training and certification by the study PD/PI. Standardized clinical evaluations of arm impairment, activity limitation, and participation restriction will also be performed during this phase at Shirley Ryan AbilityLab by the study evaluation therapist who will be blinded to intervention group. Evaluations will take place at baseline, weekly until discharge from rehabilitation, and then bimonthly until 12 months post-baseline measurement. Following discharge from rehabilitation, patients will receive follow-up evaluations bimonthly at Northwestern University Department of Physical Therapy and Human Movement Sciences. These evaluations will be conducted by a second study evaluation therapist and board-certified neurological clinical specialist following initial training and certification by the study PD/PI. The second study evaluation therapist will also serve as the backup for the first study evaluation therapist in case of illness/absence.
During in-patient rehabilitation and day-rehabilitation, experimental and comparison intervention sessions will parallel regular therapy and be conducted at Shirley Ryan AbilityLab and Streeterville Day Rehabilitation Center respectively by two Shirley Ryan AbilityLab study intervention therapists. Study intervention therapists will be initially trained and certified by the study PD/PI. Study intervention sessions will be 5 days per week during in-patient therapy and 3 days per week during day-rehabilitation. The intervention period for both groups will be ~45 minutes (truncated at 1 hour) in addition to the regular therapy schedule until discharge. Both interventions will involve performing standardized reaching exercises to outward targets displayed on a monitor. The experimental group receiving progressive abduction loading therapy will practice reaching exercises with abduction loading and the comparison group will practice reaching supported on a horizontal haptic table. All participants will have the same maximum number of sets and repetitions of exercise during sessions and the sessions will be truncated at 60 minutes of total contact time. Half of the enrolled participants are expected to transition to day-rehabilitation following in-patient rehabilitation. In day-rehabilitation, participants will continue to receive the same study intervention but only 3 days per week matching the day-rehabilitation schedule.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Abduction Loading | Experimental | Behavioral: Abduction LoadingThe intervention for the experimental group entails practicing reaching with abduction loading. |
| Supported Reaching | Active comparator | Behavioral: Supported ReachingThe intervention for the active comparator entails practicing reaching while supported. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Hemiparesis confined to one side, (CMSA Stage 2 or 3 out of 7)
- Stroke impacting parenchyma of the middle cerebral artery distribution
- Within 90 days post-stroke
- 18 to 85 years old
- No or Mild-to-moderate Aphasia (NIHSS #9 Best Language. = 0 or 1- Describe picture; No or Mild-to-moderate Aphasia)
Key exclusion criteria (6 listed)
- Premorbid and persistent disability or motor impairment of the upper extremities
- Brainstem and/or cerebellar lesion
- Comorbidity medically contraindicating motor assessments
- Any other chronic neurological condition
- Pain or hypersensitivity limiting motor assessments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Abduction LoadingAlso: Progressive Abduction Loading TherapyThe intervention for the experimental group entails practicing reaching with abduction loading. | Behavioural | Abduction Loading |
| Supported ReachingThe intervention for the active comparator entails practicing reaching while supported. | Behavioural | Supported Reaching |
Primary outcome
Change in Reaching Function
Time frame: Change in Reaching function will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Quantitative evaluation of reaching by calculating distance from reaching kinematics data during ballistic outward reaches against gravity.
4 secondary outcomes
Change in Loss of Independent Joint Control
Time frame: Change in Loss of Independent Joint Control will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Fugl-Meyer Motor Assessment
Time frame: Change in Fugl-Meyer Motor Assessment will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Action Research Arm Test
Time frame: Change in Action Research Arm Test will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Change in Stroke Impact Scale
Time frame: Change in Stroke Impact Scale will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Background: PubMed 29515514Ellis MD, Carmona C, Drogos J, Dewald JPA. Progressive Abduction Loading Therapy with Horizontal-Plane Viscous Resistance Targeting Weakness and Flexion Synergy to Treat Upper Limb Function in Chronic Hemiparetic Stroke: A Randomized Clinical Trial. Front Neurol. 2018 Feb 19;9:71. doi: 10.3389/fneur.2018.00071. eCollection 2018.
- Background: PubMed 27794362Ellis MD, Lan Y, Yao J, Dewald JP. Robotic quantification of upper extremity loss of independent joint control or flexion synergy in individuals with hemiparetic stroke: a review of paradigms addressing the effects of shoulder abduction loading. J Neuroeng Rehabil. 2016 Oct 29;13(1):95. doi: 10.1186/s12984-016-0203-0.
- Background: PubMed 19454622Ellis MD, Sukal-Moulton T, Dewald JP. Progressive shoulder abduction loading is a crucial element of arm rehabilitation in chronic stroke. Neurorehabil Neural Repair. 2009 Oct;23(8):862-9. doi: 10.1177/1545968309332927. Epub 2009 May 19.
- Derived from this study: PubMed 40685355Roth HR, Carmona C, Clark G, Gyarmaty JE, Dewald JPA, Giblin E, Harvey RL, Jaskiewicz J, Kim KA, Lancki N, Luhrsen A, Mandana A, Manikonda D, Morris A, Sheth S, Stoykov ME, Young AC, Zielke D, Ellis MD. PRALINE: study protocol for a phase IIb inpatient stroke rehabilitation randomized controlled trial investigating longitudinal outcomes after progressive abduction loading therapy. Trials. 2025 Jul 20;26(1):250. doi: 10.1186/s13063-025-08969-6.
- Individual participant dataSharing planned: Yes. Final research data will be shared openly and timely in accordance with NIH Data Sharing Policy (https://grants.nih.gov/grants/policy/data_sharing/) and NICHD Data and Specimen Hub - Data Archive Policy Statement (https://dash.nichd.nih.gov/Resource/Policies). Data sharing will occur through the primary repositories of NICHD DASH (https://dash.nichd.nih.gov/), Northwestern University DigitalHub (https://digitalhub.northwestern.edu/), and Open Science Framework (https://osf.io/). Data will be exported from the internal RedCap study data base in spreadsheet format and will be deidentified and coded. Data will be available through speaking engagements and publications, presentations at scientific symposia and seminars. Data sharing in the above repositories will be phased in time with acceptance for publication of the primary outcome paper near the end of the fifth year and then with each subsequent publication. Publications will include DOIs for the data repositories.
Related trials for Stroke, Acute
RecruitingObservational study
Stroke Hemiplegic Shoulder Pain: Ultrasound Findings and VAS (Cross-Sectional)
Hemiplegic Shoulder Pain, Stroke
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Not yet recruitingPhase 3
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Stroke, Acute Ischemic, Medium Vessel Occlusion
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael D Ellis, PT, DPT principal investigator
Northwestern University
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Abduction Loading and Supported Reaching in people with Stroke, Acute, run by Northwestern University at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Reaching Function (time frame: Change in Reaching function will be modeled from baseline, weekly (until discharge from rehabilitation, on average 4 to 10 weeks), and monthly evaluations (every-other month until 12 months post-stroke).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04118998, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.